The CEO's material sale, over three times the size of the director's, raises questions about confidence in near-term prospects. Traders should monitor upcoming earnings or clinical trial updates for potential negative catalysts.
VIR drugs
VIR drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $9.02entry
- T+1 · 8mo ago +0.44%α +0.36% · $9.06
- T+5 · 7mo ago +8.98%α +5.21% · $9.83
- T+20 · 7mo ago +11.75%α +2.03% · $10.08
- T+60 · 5mo ago +15.08%α +1.70% · $10.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology's CEO and a board director collectively sold $864K worth of shares in the past week, with the CEO accounting for 77% of the total volume. The sales occurred at market prices and represent open-market transactions, not automatic or non-cash dispositions.
Key Financial Metrics
Key Facts
- CEO Marianne De Backer sold 72,559 shares for $664,350 at $9.156 per share on April 6, 2026.
- Director Vicki Sato sold 22,000 shares for $199,617 at $9.0735 per share on April 1, 2026.
- Total insider selling cluster: $864K over a 7-day period.
- All transactions were open-market sales (Form 4 code 'S'), indicating intentional divestment.
Financial Impact
$864K in insider sales over 7 days, representing 0.066% of the company's $1.3B market cap
Risk Factors
- Insider selling, especially by the CEO, may signal reduced confidence in future performance or valuation.
- Potential for negative market perception, particularly if no clear rationale (e.g., diversification) is disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VIR-1775595151995 |
Track record
36 reports on VIR
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers